Releases
IDEAYA Begins Clinical Testing of IDE892 for MTAP-Deleted Cancers
IDEAYA Biosciences has enrolled the first patient in a Phase 1/2 trial testing IDE892, a novel PRMT5 inhibitor, in combination with its MAT2A-targeting drug IDE397. The study focuses on non-small cell lung cancer and pancreatic cancer, where MTAP-deletion creates specific vulnerabilities that researchers aim to exploit for deeper tumor responses.


























